Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Characterization and differentiation potential of rabbit mesenchymal stem cells for translational regenerative medicine.

Bakhtina A., Tohfafarosh M., Lichtler A., Arinzeh TL.

Animal Study on Face & Skin, published in In Vitro Cell Dev Biol Anim (2013) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
In Vitro Cell Dev Biol Anim (2013)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
24150687
DOI
10.1007/s11626-013-9702-5

Abstract (original English)

Mesenchymal stem cells (MSCs) derived from the adult bone marrow are multipotent stem cells that can give rise to lineages of bone, cartilage, muscle, fat, and others. The rabbit is a common preclinical model used for cardiovascular and orthopaedic applications. MSCs derived from the rabbit whole bone marrow are routinely investigated in these models for regenerative medicine applications. However, rabbit MSCs (rbMSCs) have not been extensively characterized in terms of immunophenotypic characteristics and differentiation potential and more specifically, in comparison to human MSCs (hMSCs). This study examined rbMSCs' surface antigens as well as their multipotent differentiation potential. In addition, the transduction efficiency of rbMSCs using a lentiviral vector with red fluorescent protein (RFP) as a method for labeling the cells for in vitro and in vivo use was also examined. RbMSCs were positive for CD44 and CD29 and negative for CD45 and CD14, which is similar to hMSCs, but rbMSCs did not express CD90. RbMSCs also expressed the pluripotent transcription factor, Sox2. The rbMSCs at early passages differentiated along the osteoblastic, chondrocytic, and adipocytic lineages. However, quantitative analyses demonstrated lower levels of differentiation markers for rabbit cells as compared to human cells. Transduction efficiency of 90.5% was observed for rbMSC transfected with

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsAntigens, SurfaceBone Marrow CellsCell Culture TechniquesCell DifferentiationCell ProliferationChondrocytesMaleMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research